Group 1 - The core collaboration between the company and Koser Medical focuses on the distribution of vascular interventional products, with an expected annual distribution scale of approximately 100 million yuan [1] - The actual implementation of the distribution business in 2026 may be influenced by factors such as channel expansion, indicating a degree of uncertainty [1]

Core Viewpoint - The company has entered into a distribution partnership with Koseir Medical, focusing on vascular intervention products, with an expected annual distribution scale of approximately 100 million yuan [1] Group 1 - The collaboration with Koseir Medical primarily involves the distribution of vascular intervention products [1] - The anticipated annual distribution scale from this partnership is around 100 million yuan [1] - The actual implementation of the distribution in 2026 may be influenced by factors such as channel expansion, introducing a degree of uncertainty [1]

每经AI快讯，有投资者在投资者互动平台提问：贵公司除了主营业务，有没有布局新的业务增长点 （如：脑机接口、人工智能等）？ （记者 张明双） 建发致新（301584.SZ）1月8日在投资者互动平台表示，公司没有布局脑机接口、人工智能的业务计 划。 ...

格隆汇1月6日丨建发致新(301584.SZ)在互动平台表示，公司目前销售的产品中不涉及脑机接口产品。 ...

Core Viewpoint - The company, Jianfa Zhixin (301584.SZ), is currently engaged in the distribution of medical surgical robot products and does not involve in the manufacturing or distribution of brain-computer interface products [1]. Company Operations - The company is actively involved in the distribution business of medical surgical robots [1]. - There is no involvement in the manufacturing or distribution of brain-computer interface products [1].

格隆汇1月6日丨建发致新(301584.SZ)在互动平台表示，公司目前没有通过产业投资者基金布局商业航 天、机器人、新能源和芯片等科技行业情形。公司目前并不掌握控股股东建发集团通过投资基金布局商 业航天、机器人、新能源和芯片行业的具体信息。 ...

格隆汇1月6日丨建发致新(301584.SZ)在互动平台表示，公司目前没有通过产业投资者基金布局商业航 天、机器人、新能源和芯片等科技行业情形。公司目前并不掌握控股股东建发集团通过投资基金布局商 业航天、机器人、新能源和芯片行业的具体信息。 ...

Core Viewpoint - The company has confirmed its involvement in the distribution of medical surgical robot products but does not engage in the manufacturing or distribution of brain-machine interface products [1]. Group 1 - The company operates a distribution business for medical surgical robots [1]. - The company does not manufacture or distribute brain-machine interface products [1].

Group 1 - The company is currently engaged in the distribution of medical surgical robot products [1] - The company does not involve in the manufacturing and distribution of brain-computer interface products [1]

Group 1 - The core point of the news is that Jianfa Zhixin experienced a stock price increase of 3.11% on January 5, with a trading volume of 126 million yuan, despite a net financing outflow of 451.27 million yuan for the day [1][2] - On January 5, Jianfa Zhixin had a financing buy amount of 7.2758 million yuan, with a total financing balance of 106 million yuan, representing 6.98% of its market capitalization [2] - The company, established on August 30, 2010, specializes in medical device direct sales and distribution, providing centralized operation services for medical consumables to hospitals [2] Group 2 - Jianfa Zhixin's revenue for the period from January to September 2025 reached 14.861 billion yuan, reflecting a year-on-year growth of 10.18%, while the net profit attributable to shareholders was 230 million yuan, up 45.01% year-on-year [2] - As of December 19, the number of shareholders for Jianfa Zhixin was 28,900, a decrease of 4.56% from the previous period, with an average of 1,747 circulating shares per person, an increase of 4.78% [2]